Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Processa Pharmaceuticals, Inc. - Common Stock (NQ:PCSA)

0.3036 +0.0136 (+4.69%)
Streaming Delayed Price Updated: 1:19 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Processa Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Update on Clinical Programs Enrollment
Via Investor Brand Network
Exposures COVID-19
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming Global Investment Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Names New Key Board Appointments
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q2 2022 Results, Corporate Updates
Via Investor Brand Network
Exposures Product Safety
Earnings Scheduled For November 11, 2021
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape... 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2022 Results Conference Call
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Launches New Website Focused on Rare Disease
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) CEO to Present at World Orphan Drug Congress USA
Via Investor Brand Network
Exposures Product Safety
82 Biggest Movers From Yesterday
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday. 
Via Benzinga
41 Stocks Moving In Tuesday's Mid-Day Session
Gainers Revlon, Inc. (NYSE: REV) rose 125.5% to $2.6499. Revlon’s stock dropped sharply on Monday after the company is reportedly expected to file for bankruptcy. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2022 Report, Updates
Via Investor Brand Network
Exposures Product Safety
Preview: Processa Pharmaceuticals's Earnings
Processa Pharmaceuticals (NASDAQ:PCSA) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q1 2022 Results, Provide Drug Development Update
Via Investor Brand Network
Exposures Product Safety
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
Earnings Scheduled For May 12, 2022
Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter. 
Via Benzinga
99 Biggest Movers From Yesterday
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company. 
Via Benzinga
90 Biggest Movers From Yesterday
Gainers 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Administers First Dosage in Amended Phase 1B Study
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Enrolls First Patient in PCS12852 Phase 2A Trial
Via Investor Brand Network
Processa Pharmaceuticals Earnings Preview
Processa Pharmaceuticals (NASDAQ:PCSA) is set to give its latest quarterly earnings report on Wednesday, 2022-03-30. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2022
Upgrades 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q4 2021 Results, Provide Clinical Pipeline Update
Via Investor Brand Network
Earnings Scheduled For March 30, 2022
Companies Reporting Before The Bell • Orgenesis (NASDAQ:ORGS) is likely to report earnings for its fourth quarter. • RumbleON (NASDAQ:RMBL) is estimated to report earnings for its Fiscal Year 2021. 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Issues Letter to Shareholders Eyeing ‘Transformative Year’ in 2022
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q3 2021 Financial, Corporate Results
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Results of Next-Generation Capecitabine Analysis
Via Investor Brand Network
Exposures Product Safety
Processa Pharmaceuticals Inc. to Host Q3 Results, Development Update Call
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.